Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-08-31

FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA indicates a Supplemental Application for Levetiracetam submitted by Prasco Laboratories; this represents an additional regulatory action related to the prod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVETIRACETAM (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)